Cadila Healthcare Limited (BSE:532321) acquired Sentynl Therapeutics Inc. for INR 8.3 billion on January 19, 2017. The acquisition is solely funded by Bank of Tokyo-Mitsubishi UFJ. The transaction will be EPS accretive for Cadila Healthcare Limited. Leerink Partners LLC acted as financial advisor for Sentynl. Cadila Healthcare Limited (BSE:532321) completed the acquisition of Sentynl Therapeutics Inc. on January 19, 2017. Under the terms of agreement, consideration was paid in cash. As a part of the acquisition, Sentynl has now become the wholly owned subsidiary of the Cadila Healthcare.